Schaub; Robert
Patent Applications and Registrations
Patent applications and USPTO patent grants for Schaub; Robert.The latest application filed is for "combination therapy with il-12".
- Schaub; Robert - Waltham MA
- Schaub; Robert - Pelham NH US
| Patent | Date |
|---|---|
| Combination Therapy With Il-12 App 20160022777 - Schaub; Robert ; et al. | 2016-01-28 |
| Combination Therapy App 20150165021 - Mashal; Robert ; et al. | 2015-06-18 |
| Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics Grant 8,598,327 - Schaub , et al. December 3, 2 | 2013-12-03 |
| Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder thereapeutics Grant 8,461,318 - Schaub , et al. June 11, 2 | 2013-06-11 |
| Aptamers To Tissue Factor Pathway Inhibitor And Their Use As Bleeding Disorder Thereapeutics App 20120190834 - Schaub; Robert ; et al. | 2012-07-26 |
| Aptamers To Tissue Factor Pathway Inhibitor And Their Use As Bleeding Disorder Therapeutics App 20110281938 - Schaub; Robert ; et al. | 2011-11-17 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 